Does icosapent ethyl 2 g twice daily reduce ischemic events in patients with elevated triglyceride levels despite the use of statins?
Icosapent ethyl significantly reduces the risk of ischemic events in statin-treated patients with elevated triglycerides.
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Bhatt et al. (Sat,) studied this question.